Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
First Claim
Patent Images
1. A method of upregulating a function of and/or the expression of a Hepatocyte Growth Factor (HGF) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
- contacting said cells or tissues with at least one antisense oligonucleotide 10 to 30 nucleotides in length specifically hybridizable with a natural antisense polynucleotide of the HGF gene wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 10 to 30 consecutive nucleotides within nucleotides 1 to 514 of SEQ ID NO;
2, nucleotides 1 to 936 of SEQ ID NO;
3 or 1 to 1075 nucleotides of SEQ ID NO;
4;
thereby upregulating a function of and/or the expression of the Hepatocyte Growth Factor (HGF) polynucleotide in patient cells or tissues in vivo or in vitro.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Hepatocyte Growth Factor (HGF), in particular, by targeting natural antisense polynucleotides of Hepatocyte Growth Factor (HGF). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of HGF.
-
Citations
16 Claims
-
1. A method of upregulating a function of and/or the expression of a Hepatocyte Growth Factor (HGF) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one antisense oligonucleotide 10 to 30 nucleotides in length specifically hybridizable with a natural antisense polynucleotide of the HGF gene wherein said at least one oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 10 to 30 consecutive nucleotides within nucleotides 1 to 514 of SEQ ID NO;
2, nucleotides 1 to 936 of SEQ ID NO;
3 or 1 to 1075 nucleotides of SEQ ID NO;
4;
thereby upregulating a function of and/or the expression of the Hepatocyte Growth Factor (HGF) polynucleotide in patient cells or tissues in vivo or in vitro.- View Dependent Claims (2, 11)
-
3. A method of upregulating a function of and/or the expression of a Hepatocyte Growth Factor (HGF) polynucleotide in patient cells or tissues in vivo or in vitro comprising:
contacting said cells or tissues with at least one single stranded antisense oligonucleotide of 10 to 30 nucleotides in length that specifically targets and specifically hybridizes to a region of a natural antisense oligonucleotide of the Hepatocyte Growth Factor (HGF) polynucleotide selected from SEQ ID NOS;
2, 3 or 4;
thereby upregulating a function of and/or the expression of the Hepatocyte Growth Factor (HGF) polynucleotide in patient cells or tissues in vivo or in vitro.- View Dependent Claims (4, 5, 6, 7, 8, 9, 10)
-
12. A method of preventing or treating a disease associated with at least one Hepatocyte Growth Factor (HGF) polynucleotide and/or at least one encoded product thereof, comprising:
administering to a patient a therapeutically effective dose of at least one single stranded antisense oligonucleotide of 10 to 30 nucleotides in length that specifically hybridizes to a natural antisense sequence of said at least one Hepatocyte Growth Factor (HGF) polynucleotide selected from 1 to 514 of SEQ ID NO;
2, nucleotides 1 to 936 of SEQ ID NO;
3 or 1 to 1075 nucleotides of SEQ ID NO;
4 and upregulates expression of said at least one Hepatocyte Growth Factor (HGF) polynucleotide;
thereby treating the disease associated with the at least one Hepatocyte Growth Factor (HGF) polynucleotide and/or at least one encoded product thereof.- View Dependent Claims (13)
-
14. A method of preventing or treating a skin condition associated with at least one Hepatocyte Growth Factor (HGF) polynucleotide and/or at least one encoded product thereof, comprising:
- administering to a patient having a skin condition or at risk of developing a skin condition a therapeutically effective dose of at least one single stranded antisense oligonucleotide of 10 to 30 nucleotides in length that specifically hybridizes to a natural antisense sequence of said at least one Hepatocyte Growth Factor (HGF) polynucleotide and upregulates expression of said at least one Hepatocyte Growth Factor (HGF) polynucleotide;
thereby preventing or treating the disease skin condition associated with the at least one Hepatocyte Growth Factor (HGF) polynucleotide and/or at least one encoded product thereof wherein said natural antisense sequence is selected from the group consisting of 1 to 514 of SEQ ID NO;
2, nucleotides 1 to 936 of SEQ ID NO;
3 or 1 to 1075 nucleotides of SEQ ID NO;
4. - View Dependent Claims (15, 16)
- administering to a patient having a skin condition or at risk of developing a skin condition a therapeutically effective dose of at least one single stranded antisense oligonucleotide of 10 to 30 nucleotides in length that specifically hybridizes to a natural antisense sequence of said at least one Hepatocyte Growth Factor (HGF) polynucleotide and upregulates expression of said at least one Hepatocyte Growth Factor (HGF) polynucleotide;
Specification